{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:29:34Z","timestamp":1769203774728,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Elcelyx Therapeutics, Inc."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0203946","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T17:30:15Z","timestamp":1537896615000},"page":"e0203946","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes"],"prefix":"10.1371","volume":"13","author":[{"given":"Robert R.","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Frias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4275-9245","authenticated-orcid":true,"given":"Brandon","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Skare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hemming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Bicsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"GG Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0168-8227(88)80022-6","article-title":"Metformin in the digestive tract","volume":"4","author":"N Vidon","year":"1988","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.1981.tb01206.x","article-title":"Metformin kinetics in healthy subjects and in patients with diabetes mellitus","volume":"12","author":"GT Tucker","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the intestine","volume":"51","author":"CJ Bailey","year":"2008","journal-title":"Diabetologia"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM","volume":"15","author":"CJ Bailey","year":"1992","journal-title":"Diabetes Care"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/mol.63.4.844","article-title":"Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin","volume":"63","author":"DS Wang","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/cc8885","article-title":"Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication","volume":"14","author":"A Protti","year":"2010","journal-title":"Crit Care"},{"key":"ref8","unstructured":"Glucophage (metformin hydrochloride) and Glucophage XR (extended-release) US Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; 2017."},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"RI Misbin","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc7137","article-title":"Metformin-associated lactic acidosis in an intensive care unit","volume":"12","author":"N Peters","year":"2008","journal-title":"Crit Care"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study","volume":"3","author":"SC Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/ndt\/gfn152","article-title":"Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice","volume":"23","author":"J Almirall","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/dom.12978","article-title":"Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study","volume":"19","author":"PJ Connelly","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"ref14","first-page":"24","article-title":"The status of metformin in Canada","volume":"128","author":"OJ Lucis","year":"1983","journal-title":"Canadian Medical Association journal"},{"key":"ref15","unstructured":"Glucophage Summary of Product Characteristics (United Kingdom). Feltham, Middlesex: Merck Serono; 2017."},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"SE Inzucchi","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1463-1326.2006.00691.x","article-title":"Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes","volume":"9","author":"R Brazg","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"ref18","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease","author":"C Wanner","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference","volume":"90","author":"V Perkovic","year":"2016","journal-title":"Kidney international"},{"key":"ref20","article-title":"Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease","author":"CCJ Dekkers","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"MF Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.mayocp.2014.07.013","article-title":"Hypoglycemia, chronic kidney disease, and diabetes mellitus","volume":"89","author":"M Alsahli","year":"2014","journal-title":"Mayo Clinic proceedings"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"V Papademetriou","year":"2015","journal-title":"Kidney international"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"e0174601","DOI":"10.1371\/journal.pone.0174601","article-title":"Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: A national cohort study","volume":"12","author":"YW Chu","year":"2017","journal-title":"PLoS One"},{"issue":"16","key":"ref25","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1097\/MD.0000000000000771","article-title":"Association of hypoglycemia with incident chronic kidney disease in patients with type 2 diabetes: a nationwide population-based study","volume":"94","author":"CJ Shih","year":"2015","journal-title":"Medicine"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/WNL.0000000000000711","article-title":"Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia","volume":"83","author":"TM Yu","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/db16-0032","article-title":"[11C]-Labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency","volume":"65","author":"JB Jensen","year":"2016","journal-title":"Diabetes"},{"issue":"39","key":"ref28","doi-asserted-by":"crossref","first-page":"27055","DOI":"10.1074\/jbc.M114.570564","article-title":"Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands","volume":"289","author":"N Lee","year":"2014","journal-title":"J Biol Chem"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00562061","article-title":"Pharmacokinetics of metformin after intravenous and oral administration to man","volume":"16","author":"PJ Pentikainen","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1124\/dmd.107.020180","article-title":"Mechanisms underlying saturable intestinal absorption of metformin","volume":"36","author":"WR Proctor","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00498259409043220","article-title":"Accumulation of metformin by tissues of the normal and diabetic mouse","volume":"24","author":"C Wilcock","year":"1994","journal-title":"Xenobiotica"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"e100778","DOI":"10.1371\/journal.pone.0100778","article-title":"Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus","volume":"9","author":"A Napolitano","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"FA Duca","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation. results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"JB Buse","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk","volume":"65","author":"R DeFronzo","year":"2016","journal-title":"Metabolism"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00125-016-3992-6","article-title":"Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials","volume":"59","author":"RA DeFronzo","year":"2016","journal-title":"Diabetologia"},{"issue":"7581","key":"ref37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"K Forslund","year":"2015","journal-title":"Nature"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"LJ McCreight","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"ref39","first-page":"S114","article-title":"Metformin exposure with gut-restricted delayed-release metformin in CKD Stage 4 does not exceed that of current metformin used on-label: results from population PK modelling","volume":"60","author":"G Bakris","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10543409508835097","article-title":"Dose response studies. II. Analysis and interpretation","volume":"5","author":"SJ Ruberg","year":"1995","journal-title":"Journal of biopharmaceutical statistics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"RA Bailey","year":"2014","journal-title":"BMC Res Notes"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4","volume":"41","author":"JD Lalau","year":"2018","journal-title":"Diabetes Care"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0203946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T18:40:13Z","timestamp":1662144013000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0203946"}},"subtitle":[],"editor":[{"given":"Dorit","family":"Samocha-Bonet","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0203946","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]}}}